BAM
ITCI

Blueshift Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Blueshift Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,535
Closed -$459K – 1222
2021
Q1 		$459K Buy
+13,535
New +$470K 0.05% 491
2020
Q4 		– Sell
-13,444
Closed -$345K – 919
2020
Q3 		$345K Buy
+13,444
New +$307K 0.05% 420

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Blueshift Asset Management's ITCI Position: Q2 2021 in Review

Blueshift Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2021, closing a stake of 13,535 shares — an estimated $459K sold.

Blueshift Asset Management first reported a position in ITCI in Q3 2020 and held it in 2 quarters. The position peaked at $459K in Q1 2021. 187 funds tracked by Wall St. Rank hold ITCI as of Q2 2021.

  • Blueshift Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2021 after selling out during the quarter.
  • Blueshift Asset Management sold 13,535 Intra-Cellular Therapies Inc. shares in Q2 2021, an estimated $459K.
  • Blueshift Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2020 and held it in 2 quarters.
  • Blueshift Asset Management's Intra-Cellular Therapies Inc. position peaked at $459K in Q1 2021.
  • 187 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2021.

Based on Blueshift Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.